Search Result

Isoforms Recommended:	PDGFRβ

Results for "

PDGFR-β

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PDGFR (66) AMPK (1) Apoptosis (13) Autophagy (21) Bcr-Abl (4) c-Fms (7) c-Kit (24) CDK (1) Drug Metabolite (6) EGFR (2) Ephrin Receptor (2) Ferroptosis (3) FGFR (21) FLT3 (8) IRE1 (3) Isotope-Labeled Compounds (6) Mitophagy (3) PROTACs (1) Raf (9) RET (6) Src (5) Tie (3) VEGFR (56)
By Research Areas:	Cancer (77) Cardiovascular Disease (2) Inflammation/Immunology (3)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Brivanib 3 Publications Verification BMS-540215	VEGFR Autophagy	Cancer
Brivanib (BMS-540215) is an ATP-competitive inhibitor against VEGFR2 with an IC₅₀ of 25 nM, and has moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-β .

NVP-ACC789 ACC-789; ZK202650	VEGFR PDGFR	Cancer
NVP-ACC789 is an inhibitor of human VEGFR-1, VEGFR-2 (mouse VEGFR-2), VEGFR-3 and *PDGFR-β* with IC₅₀s of 0.38, 0.02 (0.23), 0.18, 1.4 μM, respectively.

Vatalanib succinate PTK787 succinate; ZK-222584 succinate; CGP-79787 succinate	VEGFR	Cancer
Vatalanib (PTK787) succinate is a potent and orally active VEGFR inhibitor with IC₅₀s of 37 nM, 77 nM, 270 nM, 660 nM, 730 nM, 1400 nM, and 580 nM for KDR, Flt-1, Flk, Flt-4, c-Kit, c-Fms, and PDGFR-β, respectively .

SA-PA	PROTACs VEGFR PDGFR Ephrin Receptor	Cancer
SA-PA is an intracellular self-assembled PROTAC based on azide and alkyne. SA-PA is able to selectively degrade VEGFR-2, *PDGFR-β* and EphB4 proteins in U87 cells. SA-PA can be converted to PROTAC in situ by click reaction with the help of endogenous copper in tumor tissues .

Tyrphostin AG1433 hydrochloride SU1433 hydrochloride; AG1433 hydrochloride	PDGFR	Inflammation/Immunology
Tyrphostin AG 1433 is a specific and potent inhibitor of *PDGFR-β* and of KDR/Flk-1. Tyrphostin AG 1433 acts as an angiogenesis inhibitor .

BMS-605541	VEGFR PDGFR	Cancer
BMS-605541 is a selective and orally active inhibitor of VEGFR-2 kinase with an IC₅₀ value of 23 nM and K_i value of 49 nM. BMS-605541 inhibits the activity of Flk-1, VEGFR-1 and *PDGFR-β* with IC₅₀ values of 40 nM, 400 nM and 200 nM, respectively. BMS-605541 can be used for cancer research .

JNJ-10198409 1 Publications Verification	PDGFR	Cancer
JNJ-10198409 is a relatively selective, orally active, and ATP competitive *PDGF-RTK* (platelet-derived growth factor receptor tyrosine kinase) inhibitor (IC₅₀=2 nM). It is a dual-mechanism, antiangiogenic, and tumor cell antiproliferative agent. JNJ-10198409 has good activity against *PDGFR-β* kinase (IC₅₀=4.2 nM) and *PDGFR-α* kinase (IC₅₀=45 nM) .

PD-089828	FGFR PDGFR EGFR Src	Cancer
PD-089828 is an ATP competitive inhibitor of FGFR-1, *PDGFR-β* and EGFR (IC₅₀s=0.15, 1.76, and 5.47 µM, respectively) and a noncompetitive inhibitor of c-Src tyrosine kinase (IC₅₀=0.18 µM). PD-089828 also inhibits MAPK with an IC₅₀ of 7.1 µM. PD-089828 inhibits PDGF-, EGF- and bFGF-mediated tyrosine kinase receptor autophosphorylation in vitro. PD-089828 has a long-lasting cellular activity .

SU16f 1 Publications Verification	PDGFR	Cancer
SU16f is a potent and selective *PDGFRβ* inhibitor with IC₅₀s of 10 nM, 140 nM, 2.29 μM for PDGFRβ, PDGFR1, PDGFR2, respectively . Neutralization of PDGFRβ receptor by SU16f blocks the promoting role of GC-MSCs (gastric cancer-derived mesenchymal stem cells) conditioned medium in gastric cancer cell proliferation and migration .

N-Desethyl Sunitinib 5 Publications Verification SU-12662	Drug Metabolite	Cancer
N-Desethyl Sunitinib (SU-12662) is a metabolite of sunitinib. Sunitinib is a potent, ATP-competitive VEGFR, *PDGFRβ* and KIT inhibitor with K_i values of 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFRβ and KIT, respectively .

N-Desethyl Sunitinib hydrochloride 5 Publications Verification SU-12662 hydrochloride	Drug Metabolite	Cancer
N-Desethyl Sunitinib (SU-12662) (hydrochloride) is a metabolite of sunitinib. Sunitinib is a potent, ATP-competitive VEGFR, *PDGFRβ* and KIT inhibitor with K_i values of 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFRβ and KIT, respectively .

DMPQ dihydrochloride	PDGFR	Others
DMPQ dihydrochloride is a potent and selective inhibitor of human platelet-derived growth factor receptor β (PDGFRβ) with an IC₅₀ of 80 nM .

CP-673451 5+ Cited Publications	PDGFR	Cancer
CP-673451 is a potent and selective inhibitor of *PDGFR* with IC₅₀s of 10 and 1 nM for PDGFRα and PDGFRβ, respectively.

JI-101	Ephrin Receptor PDGFR VEGFR	Cardiovascular Disease Cancer
JI-101 is an orally available multi-kinase inhibitor of VEGFR2, *PDGFRβ* and EphB4 with potent anti-cancer activity.

SU 5402 5+ Cited Publications	VEGFR FGFR PDGFR	Cancer
SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC₅₀ of 20 nM, 30 nM, and 510 nM for VEGFR2, FGFR1, and *PDGFRβ*, respectively.

S116836	Bcr-Abl Apoptosis PDGFR	Cancer
S116836, a potent, orally active BCR-ABL tyrosine kinase inhibitor, blocks both wild-type as well as T315I Bcr-Abl. S116836 arrests the cells in the G0/G1 phase of cell cycle, induces apoptosis, increases ROS production, and decreases GSH production in BaF3/WT and BaF3/T315I cells. S116836 also inhibits SRC, LYN, HCK, LCK and BLK, and receptor tyrosine kinases such as FLT3, TIE2, KIT, PDGFR-β. Antitumor activies . S116836 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

SU14813 1 Publications Verification	PDGFR VEGFR c-Kit	Cancer
SU14813 is a multi-targeted receptor tyrosine kinases inhibitor with IC₅₀s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, *PDGFRβ* and KIT.

SU14813 maleate 1 Publications Verification	PDGFR VEGFR c-Kit	Cancer
SU14813 maleate is a multi-targeted receptor tyrosine kinases inhibitor with IC₅₀s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, *PDGFRβ* and KIT.

PDGFRα kinase inhibitor 1	PDGFR	Cancer
PDGFRα kinase inhibitor 1 is a highly selective type II PDGFRα kinase inhibitor with IC₅₀s of 132 nM and 6115 nM for PDGFRα and PDGFRβ, respectively .

AC710	PDGFR c-Kit FLT3	Cancer
AC710 is a potent *PDGFR* inhibitor with K_ds of 0.6, 1.57, 1, 1.3, 1.0 nM for FLT3, CSF1R, KIT, PDGFRα and PDGFRβ, respectively.

AC710 Mesylate	PDGFR	Cancer
AC710 Mesylate is a potent *PDGFR* inhibitor with K_ds of 0.6, 1.57, 1, 1.3, 1.0 nM for FLT3, CSF1R, KIT, PDGFRα and PDGFRβ, respectively.

KG5	Raf PDGFR FLT3 c-Kit	Cancer
KG5 is an orally active dual *PDGFRβ* and B-Raf allosteric inhibitor. KG5 also inhibits Flt3, KIT and c-Raf. KG5 has anticancer, antiangiogenic activities .

Gint4.T aptamer sodium	PDGFR	Cancer
Gint4.T aptamer sodium is a nuclease-resistant RNA aptamer-based antagonist targeting platelet-derived growth factor receptor beta (PDGFRβ) (Kd: 9.6 nM). Gint4.T aptamer sodium inhibits PDGFRβ heterodimerization and EGFR transactivation. It can significantly inhibit cell migration and proliferation, induce differentiation and prevent tumor growth in vivo. Gint4.T aptamer sodium specifically inhibits PDGFRβ-mediated tropism of mesenchymal stem cells (MSCs) toward the tumor microenvironment .

Orantinib 3 Publications Verification SU6668; TSU-68	PDGFR FGFR VEGFR Apoptosis	Cancer
Orantinib (SU6668; TSU-68) is a multi-targeted receptor tyrosine kinase inhibitor with K_is of 2.1 μM, 8 nM and 1.2 μM for Flt-1, *PDGFRβ* and FGFR1, respectively.

Flumatinib HHGV678	Bcr-Abl c-Kit PDGFR	Cancer
Flumatinib (HHGV678) is an orally available, selective inhibitor of Bcr-Abl. Flumatinib inhibits c-Abl, *PDGFRβ* and c-Kit with IC₅₀s of 1.2 nM, 307.6 nM and 665.5 nM, respectively .

Axitinib 15+ Cited Publications AG-013736	VEGFR PDGFR	Cancer
Axitinib is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and *PDGFRβ*, respectively.

Multi-kinase-IN-3	VEGFR PDGFR	Cancer
Multi-kinase-IN-3 (compound 2) is a potent angiokinase inhibitor. Multi-kinase-IN-3 shows inhibition activity against VEGFR-2 and *PDGFRβ, with IC₅₀* values of 58.3 and 55 nM, respectively .

Pazopanib Hydrochloride 10+ Cited Publications GW786034 Hydrochloride	PDGFR VEGFR FGFR c-Kit c-Fms Autophagy	Cancer
Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, *PDGFRβ, c-Kit, FGFR1, and c-Fms* with an IC₅₀ of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

Cediranib maleate 5+ Cited Publications AZD-2171 maleate	VEGFR Autophagy PDGFR	Cancer
Cediranib maleate (AZD-2171 maleate) is a highly potent, orally available VEGFR inhibitor with IC₅₀s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.

Cediranib 5+ Cited Publications AZD2171	VEGFR Autophagy PDGFR	Cancer
Cediranib (AZD2171) is a highly potent, orally available VEGFR tyrosine kinase inhibitor with IC₅₀s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.

Brivanib (alaninate) 3 Publications Verification BMS-582664	VEGFR Autophagy	Cancer
Brivanib alaninate (BMS-582664) is an ATP-competitive inhibitor against VEGFR2 with an IC₅₀ of 25 nM; has moderate potency against VEGFR-1 and FGFR-1, but more than 240-fold against PDGFRβ .

Pazopanib 10+ Cited Publications GW786034	VEGFR c-Kit PDGFR Autophagy FGFR	Cancer
Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, *PDGFRβ, c-Kit, FGFR1, and c-Fms* with IC₅₀s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

Sennoside B 1 Publications Verification	PDGFR	Cancer
Sennoside B is an anthraquinone glycoside, found in large quantities in leaves and pods of Senna (Cassia angustifolia) . Sennoside B can inhibit PDGF-stimulated cell proliferation by binding to PDGF-BB and its receptor and by down-regulating the PDGFR-beta signaling pathway .

Seralutinib 1 Publications Verification GB002; PK10571	PDGFR c-Fms c-Kit	Cardiovascular Disease
Seralutinib (GB002) is an inhaled PDGFRα and *PDGFRβ* inhibitor. Seralutinib also targets to CSF1R and c-KIT with IC₅₀s of 8 nM and 14 nM, respectively. Seralutinib (GB002) is used in the study for pulmonary arterial hypertension .

Regorafenib Hydrochloride 45+ Cited Publications BAY 73-4506 hydrochloride	VEGFR Autophagy PDGFR Raf RET	Cancer
Regorafenib Hydrochloride (BAY 73-4506 hydrochloride) is a multi-target inhibitor for VEGFR1/2/3, *PDGFRβ, Kit, RET* and Raf-1 with IC₅₀s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively .

Sunitinib 45+ Cited Publications SU 11248	VEGFR PDGFR IRE1 Mitophagy Autophagy Apoptosis	Cancer
Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC₅₀s of 80 nM and 2 nM for VEGFR2 and *PDGFRβ, respectively . Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α* by inhibiting autophosphorylation and consequent RNase activation .

PDGFRα/β/VEGFR-2-IN-1	PDGFR VEGFR	Cancer
PDGFRα/β/VEGFR-2-IN-1 (6f), a multiple PDGFRα/ß and VEGFR-2 tyrosine kinase inhibitor, particularly targets PDGFRα, PDGFRβ, and VEGFR-2 kinases with Nano molar concentrations .

Regorafénib N-oxyde (M2)	Drug Metabolite PDGFR	Cancer
Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC₅₀s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.

Sunitinib Malate 45+ Cited Publications SU 11248 Malate	PDGFR VEGFR IRE1 Mitophagy Autophagy Apoptosis	Cancer
Sunitinib Malate (SU 11248 Malate) is a multi-targeted receptor tyrosine kinase inhibitor with IC₅₀s of 80 nM and 2 nM for VEGFR2 and *PDGFRβ, respectively . Sunitinib Malate, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α* by inhibiting autophosphorylation and consequent RNase activation .

Toceranib SU11654; PHA 291639E	PDGFR VEGFR c-Kit	Cancer
Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits *PDGFR, VEGFR, and Kit* with K_is of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib phosphate (SU11654 phosphate) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors .

Toceranib phosphate SU11654 phosphate; PHA 291639E phosphate	PDGFR VEGFR c-Kit	Cancer
Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits *PDGFR, VEGFR, and Kit* with K_is of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib phosphate (SU11654 phosphate) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors .

PDGFR-IN-1	PDGFR Apoptosis	Cancer
PDGFR-IN-1 (compound 7m) is a potent and orally active *PDGFR* (platelet-derived growth factor receptor) inhibitor, with IC₅₀ values of 2.4 and 0.9 nM for PDGFRα and *PDGFRβ, respectively. PDGFR*-IN-1 displays robust antitumor effects and low toxicity, and can be used to study osteosarcoma .

CP-547632	VEGFR FGFR	Cancer
CP-547632 is an orally active, ATP-competitive and potent VEGFR-2 and FGF kinases inhibitor with IC₅₀s of 11 nM and 9 nM, respectively. CP-547632 is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 has antitumor efficacy .

Cat. No.	Product Name	Type

HY-10407G

SU 5402 (GMP)	Fluorescent Dye
SU 5402 (GMP) is SU 5402 (HY-10407) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC₅₀ of 20 nM, 30 nM, and 510 nM for VEGFR2, FGFR1, and *PDGFRβ*, respectively .

HY-50751G

Linifanib (GMP)

ABT-869 (GMP); AL-39324 (GMP)

Fluorescent Dye

Linifanib (ABT-869) (GMP) is Linifanib (HY-50751) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Linifanib is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC₅₀s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib (GMP) promotes the generation and reprogramming of iPSCs from somatic cells .

Cat. No.	Product Name	Type

HY-10407G

SU 5402 (GMP)	Biochemical Assay Reagents
SU 5402 (GMP) is SU 5402 (HY-10407) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC₅₀ of 20 nM, 30 nM, and 510 nM for VEGFR2, FGFR1, and *PDGFRβ*, respectively .

HY-50751G

Linifanib (GMP)

ABT-869 (GMP); AL-39324 (GMP)

Biochemical Assay Reagents

Species:	Human (2) Canine (1)
Tag:	His (3) Avi (2)
Source:	HEK293 (2) Sf9 insect cells (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P78194

	PDGF R beta Protein, Human (Biotinylated, HEK293, His-Avi) JTK12; PDGF R beta; PDGFR; PDGFR1; PDGFRB; CD140B; PDGFR-2; PDGFR-β; PDGF R β	Human	HEK293
	PDGF Rβ protein is integral in embryonic development and regulates cell proliferation, survival, differentiation, chemotaxis, migration, and vascular development. It crucially recruits pericytes and smooth muscle cells to the endothelium, promoting vascular smooth muscle cell migration and neointimal formation at the site of injury. PDGF R beta Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived PDGF R beta protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of PDGF R beta Protein, Human (Biotinylated, HEK293, His-Avi) is 498 a.a., with molecular weight of 78-115 kDa.

HY-P700810

	PDGF R beta Protein, Canine (HEK293, His) JTK12; PDGF R beta; PDGFR; PDGFR1; PDGFRB; CD140B; PDGFR-2; PDGFR-β; PDGF R β	Canine	HEK293
	PDGF R beta Protein is a tyrosine protein kinase that plays an important role in the regulation of embryonic development, cell proliferation, survival, differentiation, chemotaxis and migration. PDGF R beta Protein, Canine (HEK293, His) is the recombinant canine-derived PDGF R beta protein, expressed by HEK293 , with C-His labeled tag. The total length of PDGF R beta Protein, Canine (HEK293, His) is 501 a.a., with molecular weight of 70-100 kDa.

HY-P702756

	PDGF R beta Protein, Human (Biotinylated, sf9, His, Avi) PDGFRB; platelet-derived growth factor receptor, beta polypeptide; PDGFR; platelet-derived growth factor receptor beta; CD140b; JTK12; PDGFR1; PDGFR-beta; PDGF-R-beta; CD140 antigen-like family member B; platelet-derived growth factor receptor 1; beta-type platelet-derived growth factor receptor; CD140B; PDGFR-1	Human	Sf9 insect cells

Cat. No.	Product Name	Chemical Structure

HY-10873S

N-Desethyl Sunitinib-d5
N-Desethyl Sunitinib-d₅ is the deuterium labeled N-Desethyl Sunitinib. N-Desethyl Sunitinib (SU-12662) is a metabolite of sunitinib. Sunitinib is a potent, ATP-competitive VEGFR, PDGFRβ and KIT inhibitor with Ki values of 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFRβ and KIT, respectively[1].

HY-10208S

Pazopanib-d6
Pazopanib-d₆ is the deuterium labeled Pazopanib. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-10065S

Axitinib-13C,d3
Axitinib- ¹³C,d₃ is a ¹³C-labeled and deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively.

HY-13904S

Flumatinib-d3
Flumatinib-d₃ is deuterium labeled Flumatinib. Flumatinib (HHGV678) is an orally available, selective inhibitor of Bcr-Abl. Flumatinib inhibits c-Abl, PDGFRβ and c-Kit with IC50s of 1.2 nM, 307.6 nM and 665.5 nM, respectively[1].

HY-10255AS1

Sunitinib-d4
Sunitinib-d₄ is the deuterium labeled Sunitinib. Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively[1]. Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation[2].

HY-10065S1

Axitinib-d3
Axitinib-d₃ (AG-013736-d3) is deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively[1].

HY-W758126

(R)-Brivanib alaninate-d4
(R)-Brivanib alaninate-d₄ is the deuterium-labeled Brivanib (alaninate) (HY-10336). Brivanib alaninate (BMS-582664) is an ATP-competitive inhibitor against VEGFR2 with an IC₅₀ of 25 nM; has moderate potency against VEGFR-1 and FGFR-1, but more than 240-fold against PDGFRβ .

HY-10330S

Toceranib-d8
Toceranib-d₈ is the deuterium labeled Toceranib. Toceranib (SU11654) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib (SU11654) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors[1][2].

HY-10331S1

Regorafenib-13C,d3
Regorafenib- ¹³C,d₃ is the ¹³C- and deuterium labeled Regorafenib. Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively.

HY-10208S1

Pazopanib-13C,d3
Pazopanib- ¹³C,d₃ is the deuterium and ¹³C labeled Pazopanib[1]. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively[2][3].

HY-12009S

Pazopanib-13C,d3 hydrochloride
Pazopanib- ¹³C,d₃ (hydrochloride) is the deuterium and ¹³C labeled Pazopanib hydrochloride[1]. Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively[2][3].

HY-50905S

Dovitinib-d8
Dovitinib-d₈ is the deuterium labeled Dovitinib. Dovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively[1][2].

HY-I0678S1

Regorafénib N-oxyde (M2)-13C,d3
Regorafénib N-oxyde (M2)- ¹³C,d₃ is the ¹³C- and deuterium labeled Regorafénib N-oxyde (M2). Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.

HY-I0678S

Regorafénib N-oxyde-d3 (M2)
Regorafénib N-oxyde-d₃(M2) is the deuterium labeled Regorafénib N-oxyde M2[1]. Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively[2].

HY-10201S2

Sorafenib-13C,d3

1 Publications Verification

Sorafenib- ¹³C,d₃ is the ¹³C- and deuterium labeled Sorafenib. Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator[1].

Cat. No.	Product Name	Application	Reactivity

HY-P80278

*Phospho-PDGFR beta* (Y740) Antibody**	WB, ICC/IF	Human, Rat
Phospho-PDGFR beta (Y740) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 124 kDa, targeting to Phospho-PDGFR beta (Y740). It can be used for WB,ICC/IF assays with tag free, in the background of Human, Rat.

HY-P82180

PDGFR beta Antibody (YA1925) PDGFRB; PDGFR; PDGFR1; Platelet-derived growth factor receptor beta; PDGF-R-beta; PDGFR-beta; Beta platelet-derived growth factor receptor; Beta-type platelet-derived growth factor receptor; CD140 antigen-like family member B; Platelet-deri	WB, IP	Human, Mouse, Rat

HY-P83317

*Phospho-PDGFR beta* (Tyr740) Antibody (YA3062)** PDGFRB; PDGFR; PDGFR1; Platelet-derived growth factor receptor beta; PDGF-R-beta; PDGFR-beta; Beta platelet-derived growth factor receptor; Beta-type platelet-derived growth factor receptor; CD140 antigen-like family member B; Platelet-deri	WB, ICC/IF	Mouse, Rat

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

PDGFR-β

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Natural
Products